scholarly journals New Noninvasive Modalities in Coronary Angiography - Diagnostic Values of New Biomarkers for Cardiovascular Disease

10.5772/18213 ◽  
2011 ◽  
Author(s):  
Yilmaz. N ◽  
Yegin A ◽  
Aykal G.
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Angiography ◽  
Diagnostic Values ◽  
New Biomarkers

Coagulation Factor XIII and Cardiovascular Disease in UK Asian Patients Undergoing Coronary Angiography

2001 ◽  
Vol 85 (03) ◽  
pp. 408-411 ◽  
Author(s):  
Michael Mansfield ◽  
Peter Grant ◽  
Darren Warner
Keyword(s):  
Insulin Resistance ◽  
Cardiovascular Disease ◽  
Coronary Angiography ◽  
Factor Xiii ◽  
Coagulation Factor ◽  
Asian Population ◽  
B Subunit ◽  
Asian Patients ◽  
Coagulation Factor Xiii ◽  
The Uk

SummaryPossession of the coagulation factor XIII Val34Leu (FXIIIVal34Leu) polymorphism is associated with protection against myocardial infarction (MI) in Caucasians, in the absence of features of insulin resistance. The role of this polymorphism in the UK Asian population, with its high prevalence of insulin resistance and ischaemic heart disease, is unknown. We investigated the frequency of genotypes at this polymorphism, and measures of circulating FXIII in a group of UK Asians attending for coronary angiography. Genotype at the FXIIIVal34Leu polymorphism was not associated with MI. FXIII B-subunit levels correlated with waist: hip ratio (r = 0.19, p 0.005), HbA1c (r = 0.18, p 0.05), fasting triglycerides (r = 0.21, p 0.005), total cholesterol (r = 0.29, p 0.0005) and PAI-1 antigen (r = 0.24, p 0.005). An association between FXIIIVal34Leu and FXIII cross-linking activity was confirmed in these subjects (one-way ANOVA p 0.0005). This evidence does not support the hypothesis that FXIIIVal34Leu is protective against MI in the UK Asian population. FXIII B-subunit levels are strongly linked to risk factors for cardiovascular disease, suggesting an underlying association with insulin resistance.

Hyperhomocysteinemia Measured by Immunoassay: A Valid Measure of Coronary Artery Atherosclerosis

2004 ◽  
Vol 128 (11) ◽  
pp. 1263-1266
Author(s):  
Michele T. Stauffenberg ◽  
Richard A. Lange ◽  
L. David Hillis ◽  
Joaquin Cigarroa ◽  
Rebecca M. Hsu ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Artery ◽  
Coronary Angiography ◽  
High Performance ◽  
Coronary Artery Stenosis ◽  
Artery Stenosis ◽  
Valid Measure ◽  
Atherosclerotic Burden ◽  
Coronary Artery Atherosclerosis ◽  
Folate And Vitamin B12

Abstract Context.—Homocysteine is emerging as a novel marker of atherothrombosis. Its role as an independent risk factor for cardiovascular disease is generally accepted. There is scanty data correlating homocysteine levels measured by immunoassay with cardiovascular disease. We previously validated a fluorescence polarization immunoassay for measuring homocysteine, which compared favorably with high performance liquid chromatography. Objective.—To determine if homocysteine levels measured by immunoassay correlate with extent of atherosclerotic burden, as represented by degree of coronary artery stenosis determined by coronary angiography. Design.—Fasting plasma samples were obtained from patients undergoing coronary angiography (N = 165). Homocysteine levels were measured by immunoassay and coronary artery stenosis was determined by coronary angiography. Results.—Median coronary artery stenosis for the 3 homocysteine subgroups, less than 1.35, 1.35 to 6.75, and greater than 6.75 mg/L (<10, 10–15, and >15 μmol/L), was 75%, 90%, and 99%, respectively (P = .01 for trend). Also, folate and vitamin B12 levels decreased with increasing homocysteine levels (P = .01 and .04, respectively, for trend). Spearman's correlation showed a significant association between homocysteine level and coronary artery stenosis (r = 0.20; P = .009). When men and women were examined separately, the correlation was significant only for women (r = 0.30; P = .01). Conclusion.—Homocysteine levels, as measured by immunoassay, show a positive correlation with cardiovascular disease in women. Thus, this is a valid measure of atherosclerotic burden and, therefore, a reliable addition to the established laboratory repertoire for the assessment of cardiovascular disease.

scholarly journals Urinary Vitamin D Binding Protein and KIM-1 Are Potent New Biomarkers of Major Adverse Renal Events in Patients Undergoing Coronary Angiography

PLoS ONE ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. e0145723 ◽  
Author(s):  
Lyubov Chaykovska ◽  
Fabian Heunisch ◽  
Gina von Einem ◽  
Markus L. Alter ◽  
Carl-Friedrich Hocher ◽  
...  
Keyword(s):  
Vitamin D ◽  
Coronary Angiography ◽  
Binding Protein ◽  
Vitamin D Binding Protein ◽  
New Biomarkers

scholarly journals Lipid Profile of the Patient with Acute Coronary Syndromes Undergoing Coronary Angiography (CAG) in Rural Costal Region of Maharashtra

2021 ◽  
Vol 28 (4) ◽  
pp. 397-400
Author(s):  
Deshpande Janhavi JAYWANT ◽  
◽  
Amit BHALERAO ◽  
Vikas RATNAPARKHI ◽  
Suryakant NISALE ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Heart Disease ◽  
Acute Coronary Syndrome ◽  
Coronary Angiography ◽  
Total Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Low Density ◽  
Coronary Syndrome

Background: Coronary Heart Disease (CHD) is widely prevalent across the globe and significantly high level of Cholesterol in circulation is a single major risk factor associated with coronary heart disease. It is well established that cardiovascular disease is associated with hypertension and elevated blood levels of low-density lipoprotein (LDL), total cholesterol, and triglycerides. In disparity, a low level of high-density lipoprotein (HDL) is a risk factor for mortality from cardiovascular disease. Aim: The present study was conducted with the aim to assess the lipid profile in patients of Acute Coronary Syndrome (ACS) undergoing coronary angiography (CAG) in rural coastal population. Patients and Methods: The present study was done on 62 patients with Acute Coronary Syndrome (ACS) undergoing coronary angiography (CAG) Serum levels of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were examined in biochemical laboratory of the hospital. Coronary angiography was performed for the presence of lesions. Results: 43.5% of the patients (n=27) were elderly (age>60 years). Approximately 82% of the patients (n=51) aged more than 50 years. Males outnumbered females with a ratio of 2.4:1. 71% of the patients were males. Mean cholesterol levels were 177.86 mg/dl. Approx 3/4th of the patients (n=41) had cholesterol level <200 mg/Dl. Mean triglycerides levels in the patients were 158.29 mg/dl. Only 11 patients out of 62 CAD patients had abnormal triglycerides. Mean LDL level was 119.5 mg and Mean HDL level was 34.5 mg %. The high plasma concentration of low-density lipoprotein (LDL-C) in 30% and the low plasma concentration of high-density lipoprotein (HDL-C) n 33% of patients were important abnormal findings in our patients. Conclusion: Dyslipidemia as in form of very low levels of HDL cholesterol with comparatively high levels of LDL-c with near normal total Cholesterol and triglyceride levels associated with ACS in our rural costal region of Maharashtra.

scholarly journals Cathepsin S as an early biomarker for cardiovascular disease in chronic kidney disease patients

2022 ◽  
Author(s):  
Satyendra Kumar Sonkar ◽  
Prashant Kumar Singh ◽  
Sharad Chandra ◽  
Gyanendra Kumar Sonkar ◽  
Vivek Bhosale ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Complete Blood Count ◽  
Early Stage ◽  
Premature Mortality ◽  
Cathepsin S ◽  
Early Stages ◽  
Early Biomarker ◽  
New Biomarkers

Abstract Introduction: A high incidence of cardiovascular disease (CVD) events and premature mortality is observed in patients with chronic kidney disease (CKD). Thus, new biomarkers that may help predict the development of CVD in early stages of CKD are being investigated along with other traditional risk factors. Objective: To investigate cathepsin S as an early biomarker for CVD in patients with CKD. Methods: A total of 64 patients with CKD were included and classified into 2 groups: CKD patients with established CVD and CKD patients with non-established CVD. All patients were submitted to routine investigations including complete blood count, random blood sugar, glycated hemoglobin (HbA1c), serum electrolytes, urea, creatinine, total protein, total albumin, calcium total, phosphorous, uric acid, vitamin D, parathormone, lipid profile, liver function test, measurement of serum cathepsin S (Cat S), and 2D Echo of the heart. Results: The level of serum Cat S was increased in CKD patients with CVD (p <0.05) as well as in later stages of CKD (p <0.05). CVD was also more common in patients in early stage CKD. In early stages CKD, Cat S and CVD were positively correlated. Conclusion: These findings suggest that serum Cat S might be useful as an early biomarker for CVD in CKD patients.

scholarly journals Myocardial Biomarkers for Prediction of Cardiovascular Disease

2009 ◽  
Vol 26 (5-6) ◽  
pp. 235-246 ◽  
Author(s):  
Johan Sundström
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
General Population ◽  
Risk Prediction ◽  
Cardiovascular Events ◽  
Troponin I ◽  
Adverse Outcome ◽  
Unmet Need ◽  
Vast Number ◽  
New Biomarkers

The identification of those persons in the population who have the highest risk of future cardiovascular events is important for targeting intensive preventive efforts. This can be reliably done using a handful of long since established risk factors. The unmet need for new molecular biomarkers for prediction of cardiovascular events in the general population is therefore low. In order for a new biomarker to be used clinically for risk prediction, a statistically significant association of levels of the biomarker to adverse outcome is not enough, but the biomarker should also be demonstrated to add discriminative capacity beyond established risk factors. In contrast to the limited value of new biomarkers for risk prediction, their usefulness for unraveling the pathophysiology of cardiovascular disease is large. The myocardium is the source of a vast number of interesting biomarkers, of which a few may be useful for risk prediction in the general population. Two of these, troponin-I and the N-terminal fragment of brain natriuretic peptide, have passed tests of added discriminatory value. Numerous other biomarkers produced by cardiomyocytes or non-cardiomyocytes in the myocardium are promising, and if they are not proven useful for risk prediction, they will unquestionably enhance our understanding of cardiovascular disease.

scholarly journals Diagnostic potential of circulating LncRNAs in human cardiovascular disease: a meta-analysis

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Fei Luo ◽  
Tao Wang ◽  
Lini Zeng ◽  
Shanshan Zhu ◽  
Wenjun Cao ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Likelihood Ratio ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Negative Likelihood Ratio ◽  
Reference Value ◽  
Diagnostic Odds Ratio ◽  
Population Based ◽  
Diagnostic Potential ◽  
Diagnostic Values

Cardiovascular disease (CVD) is a major killer of the human population around the world. Identifying effective diagnostic biomarkers for CVDs is particularly important in order to guide optimizing treatment. Accumulating evidence on aberrantly regulated circulating long non-coding RNAs (LncRNAs) promise to serve as a diagnostic or prognostic biomarker for various types of CVDs. We summarized studies to identify the potential diagnostic values of LncRNAs in CVD patients. We included articles reporting on the association between LncRNAs and diagnosis in CVDs. We calculated sensitivities, specificities, and area under the curves of LncRNAs. The pooled overall sensitivity and specificity for LncRNAs expression profile in differentiating CVD patients from controls (non-CVDs or healthy subjects) were 0.74 (95%CI 0.68–0.80) and 0.81 (95%CI 0.76–0.85), respectively; the overall positive likelihood ratio, 3.9 (95%CI 3.1–4.9); the negative likelihood ratio, 0.32 (95%CI 0.25–0.40); corresponding to an area under curve of 0.85 (95%CI 0.82–0.88) and overall diagnostic odds ratio 12 (95%CI 9–18). Subgroup analysis showed that the detection of LncRNAs expression in plasma substantially improved the diagnostic accuracy. Likewise, meta-regression analysis indicated that the detection method and sample size were the main source of heterogeneity. All these results suggested a relatively good reference value of LncRNAs as auxiliary biomarkers for CVDs, and should be considered in cases where the diagnosis is uncertain. Population-based prospective cohort studies are warranted to confirm our findings.

Immediate and LAte Adverse Reactions in Coronary Angiography

1996 ◽  
Vol 37 (1P1) ◽  
pp. 218-222 ◽  
Author(s):  
S.-G. Fransson ◽  
G. Stenport ◽  
M. Andersson
Keyword(s):  
Myocardial Infarction ◽  
Cardiovascular Disease ◽  
Coronary Angiography ◽  
Contrast Media ◽  
Contrast Medium ◽  
Left Coronary Artery ◽  
Adverse Reactions ◽  
Parallel Study ◽  
Double Blind ◽  
Blood Pressures

Purpose and Methods: In 120 patients in a double-blind, randomized, parallel study, iodixanol (Visipaque), a nonionic dimer isotonic with blood, was compared with ioxaglate (Hexabrix), an ionic low-osmolar dimer, in coronary angiography regarding early and late adverse reactions. Haemodynamic and electrophysiologic parameters were also analyzed. Results: Visipaque resulted in significantly fewer early adverse contrast medium-related reactions (p<0.05). Visipaque also demonstrated significantly fewer effects on electrophysiologic parameters. Both contrast media reduced systolic and diastolic blood pressures at the 1st injection in the left coronary artery. Late adverse reactions were unusual with both contrast media and occurred only as urticaria with a frequency of 1.7%, which is lower than reported in i.v. studies. One serious adverse reaction, a myocardial infarction in a male patient with severe cardiovascular disease, occurred in the Visipaque group. This event was considered to be procedure- and disease-related rather than related to the type of contrast medium used. Conclusion: We found Visipaque safe for coronary angiography, causing fewer early adverse reactions than Hexabrix and also fewer effects on electrophysiologic parameters. Late adverse reactions seemed to be unusual with intra-arterial administration of contrast media.

Sign in / Sign up

Export Citation Format

Share Document